450 related articles for article (PubMed ID: 11845943)
1. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris.
Thiboutot D; Gold MH; Jarratt MT; Kang S; Kaplan DL; Millikan L; Wolfe J; Loesche C; Baker M
Cutis; 2001 Oct; 68(4 Suppl):10-9. PubMed ID: 11845943
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris.
Egan N; Loesche MC; Baker MM
Cutis; 2001 Oct; 68(4 Suppl):20-4. PubMed ID: 11845944
[TBL] [Abstract][Full Text] [Related]
3. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris.
Cunliffe WJ; Danby FW; Dunlap F; Gold MH; Gratton D; Greenspan A
Eur J Dermatol; 2002; 12(4):350-4. PubMed ID: 12095880
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV).
Tirado-Sánchez A; Espíndola YS; Ponce-Olivera RM; Bonifaz A
J Cosmet Dermatol; 2013 Jun; 12(2):103-7. PubMed ID: 23725303
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne].
Alirezai M; Meynadier J; Jablonska S; Czernielewski J; Verschoore M
Ann Dermatol Venereol; 1996; 123(3):165-70. PubMed ID: 8761775
[TBL] [Abstract][Full Text] [Related]
7. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
Kakita L
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
[TBL] [Abstract][Full Text] [Related]
8. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients.
Zhu XJ; Tu P; Zhen J; Duan YQ
Cutis; 2001 Oct; 68(4 Suppl):55-9. PubMed ID: 11845949
[TBL] [Abstract][Full Text] [Related]
9. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris.
Nyirady J; Grossman RM; Nighland M; Berger RS; Jorizzo JL; Kim YH; Martin AG; Pandya AG; Schulz KK; Strauss JS
J Dermatolog Treat; 2001 Sep; 12(3):149-57. PubMed ID: 12243706
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial.
Shalita A; Weiss JS; Chalker DK; Ellis CN; Greenspan A; Katz HI; Kantor I; Millikan LE; Swinehart T; Swinyer L; Whitmore C; Baker M; Czernielewski J
J Am Acad Dermatol; 1996 Mar; 34(3):482-5. PubMed ID: 8609263
[TBL] [Abstract][Full Text] [Related]
11. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial.
Ioannides D; Rigopoulos D; Katsambas A
Br J Dermatol; 2002 Sep; 147(3):523-7. PubMed ID: 12207595
[TBL] [Abstract][Full Text] [Related]
12. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
[TBL] [Abstract][Full Text] [Related]
13. The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial.
Babaeinejad SH; Fouladi RF
J Drugs Dermatol; 2013 Sep; 12(9):1033-8. PubMed ID: 24002152
[TBL] [Abstract][Full Text] [Related]
14. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.
Eichenfield LF; Draelos Z; Lucky AW; Hebert AA; Sugarman J; Stein Gold L; Rudisill D; Liu H; Manna V
J Drugs Dermatol; 2013 Jun; 12(6):611-8. PubMed ID: 23839175
[TBL] [Abstract][Full Text] [Related]
15. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study.
Gonzalez P; Vila R; Cirigliano M
J Cosmet Dermatol; 2012 Dec; 11(4):251-60. PubMed ID: 23174047
[TBL] [Abstract][Full Text] [Related]
16. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years.
Keating GM
Am J Clin Dermatol; 2011 Dec; 12(6):407-20. PubMed ID: 21967116
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
[TBL] [Abstract][Full Text] [Related]
18. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial.
Capizzi R; Landi F; Milani M; Amerio P
Br J Dermatol; 2004 Aug; 151(2):481-4. PubMed ID: 15327558
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene.
Goreshi R; Samrao A; Ehst BD
J Drugs Dermatol; 2012 Dec; 11(12):1422-6. PubMed ID: 23377511
[TBL] [Abstract][Full Text] [Related]
20. Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants.
Andres P; Pernin C; Poncet M
Cutis; 2008 Mar; 81(3):278-84. PubMed ID: 18441854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
